Anti-TNFR2 antibody and use thereof
AssigneesJiangsu Simcere Pharmaceutical Co., Ltd., Simcere Bio-Pharmaceutical Technology., Ltd.
InventorsXinyan Zhao, Xiaofeng Zhao, Shiqiang Lu, Ran Pang, Xinxin Li, Jinsheng Ren
Life of this patent
Estimating the term…
Abstract
Provided is an antibody or an antigen-binding fragment thereof capable of specifically binding to TNFR2, wherein the antibody or the antigen-binding fragment thereof is capable of regulating the function of immune cells and may be used as a medicament to treat diseases related to immune-related disorders, such as tumors. A polynucleotide encoding the antibody or antigen-binding fragment thereof and a pharmaceutical composition comprising the antibody or antigen binding fragment thereof are also provided.
Claims12
An antibody or antigen binding fragment thereof which specifically binds to TNFR2, comprising:
- (i) heavy chain CDR combinations of CDR1-VH, CDR2-VH, and CDR3-VH, wherein CDR1-VH comprises the sequence of SEQ ID NO:
- 74, CDR2-VH comprises the sequence of SEQ ID NO:
- 75, and CDR3-VH comprises the sequence of SEQ ID NO:
- 76 by IMGT numbering;
- and
- light chain CDR combinations of CDR1-VL, CDR2-VL, and CDR3-VL, wherein CDR1-VL comprises the sequence of SEQ ID NO:
- 80, CDR2-VL comprises the sequence of SEQ ID NO:
- 81, and CDR3-VL comprises the sequence of SEQ ID NO:
- 82 by IMGT numbering;
- or
- (ii) heavy chain CDR combinations of CDR1-VH, CDR2-VH, and CDR3-VH, wherein CDR1-VH comprises the sequence of SEQ ID NO:
- 71, CDR2-VH comprises the sequence of SEQ ID NO:
- 72, and CDR3-VH comprises the sequence of SEQ ID NO:
- 73 by KABAT numbering;
- and
- light chain CDR combinations of CDR1-VL, CDR2-VL, and CDR3-VL, wherein CDR1-VL comprises the sequence of SEQ ID NO:
- 77, CDR2-VL comprises the sequence of SEQ ID NO:
- 78, and CDR3-VL comprises the sequence of SEQ ID NO:
- 79 by KABAT numbering.
Dependencies are inferred from the claim text.